Posted by Michael Wonder on 13 Sep 2018
Improving understanding of biosimilars in the EU
13 September 2018 - New information material made available in several European languages.
The EMA and the European Commission have published additional information material on biosimilar medicines, as part of their ongoing collaboration to improve understanding of biosimilars across the European Union. A biosimilar is biological medicine that is highly similar in all essential aspects to a ‘reference’ biological medicine already authorised.
The new material includes an animated video for patients that explains key facts on biosimilar medicines and how EMA works to ensure that they are as safe and effective as their reference biological medicines.
